Blood test may track ovarian cancer treatment response
Part of Cancer, Women’s health & pregnancy clinical trials.
This study checks whether a blood test (ctDNA) can show how well ovarian, fallopian tube, or primary peritoneal cancer treatment is working. If the test reliably reflects response, it could help doctors adjust treatment earlier and more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ovarian cancer (or cancer of the fallopian tube or the lining of the abdomen) for the first time and received initial treatment
- Your cancer diagnosis was confirmed by pathology as epithelial type
- Your cancer is stage II, III, or IV, and surgery is planned after evaluation
- You are 18 years or older and can understand the study and sign consent
- You plan to use standard first-line targeted treatment drugs that your care team recommends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
This trial is testing a special blood test (called personalized ctDNA MRD) to see if it can give early warning about cancer returning after treatment. If you have cervical cancer that can be treated with surgery or chemoradiation, and you haven't had treatment yet, you may be eligible.
This study checks whether a special blood test (circulating tumor DNA) can help find ovarian cancer when it’s suspected. It may help doctors diagnose more accurately and sooner, so the right treatment can start sooner.
This study collects a blood sample before you have surgery or a biopsy for an ovarian mass. Researchers will test whether a new blood test can accurately identify ovarian cancer by looking at DNA patterns in your blood. The results will help doctors understand if this blood test could help detect ovarian cancer earlier in the future.
This study looks for cancer DNA in your blood to understand advanced ovarian cancer better. It helps doctors see how the disease changes over time and may improve future treatments.
This study is for women with advanced ovarian cancer who have finished first treatment and are in complete remission. It uses a blood test to look for tiny amounts of leftover cancer cells, which could help guide future care.
Hear when a new High Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.